Close

Aerie Pharma (AERI) Announces Statistically Significant Data from Roclatan Phase 3 Mercury 1 Trial

September 14, 2016 4:02 PM EDT Send to a Friend
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) reported the successful 90-day primary efficacy results of its 12-month Phase 3 “Mercury 1” clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login